Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects

被引：263

作者：

Allez, Matthieu ^{[1
,2
]}

Karmiris, Konstantinos ^{[3
]}

Louis, Edouard ^{[4
]}

Van Assche, Gert ^{[5
]}

Ben-Horin, Shomron ^{[6
]}

Klein, Amir ^{[7
]}

Van der Woude, Janneke ^{[8
]}

Baert, Filip ^{[9
]}

Eliakim, Rami ^{[7
]}

Katsanos, Konstantinos ^{[10
]}

Brynskov, Jorn ^{[11
]}

Steinwurz, Flavio ^{[12
]}

Danese, Silvio ^{[13
]}

Vermeire, Severine ^{[5
]}

Teillaud, Jean-Luc ^{[14
,15
]}

Lemann, Marc ^{[1
]}

Chowers, Yehuda ^{[7
]}

机构：

[1] Univ Paris 07, Hop St Louis, APHP, Dept Gastroenterol, F-75010 Paris, France

[2] INSERM, U940, Equipe Avenir, F-75654 Paris 13, France

[3] Venizele Gen Hosp, Iraklion, Crete, Greece

[4] Univ Liege, CHU Liege, Dept Gastroenterol, B-4000 Liege, Belgium

[5] Univ Hosp Leuven, Div Gastroenterol, Louvain, Belgium

[6] Tel Aviv Univ, Sackler Sch Med, Sheba Med Ctr, Tel Aviv, Israel

[7] Technion Israel Inst Technol, Rappoport Sch Med, Dept Gastroenterol, Haifa, Israel

[8] Erasmus MC Univ Med Ctr, Dept Gastroenterol & Hepatol, Rotterdam, Netherlands

[9] H Hart Hosp Roeselare, Roeselare, Belgium

[10] Univ Hosp Ioannina, Dept Internal Med 1, Hepatogastroenterol Unit, Ioannina, Greece

[11] Herlev Hosp, Dept Gastroenterol, Copenhagen, Denmark

[12] Hosp Israelita Albert Einstein, Sao Paulo, Brazil

[13] IRCCS Gastroenterol, Ist Clin Humanitas, Div Gastroenterol, Rozzano, Italy

[14] Univ Paris 06, INSERM, UMR S 872, Ctr Rech Cordeliers, Paris, France

[15] Univ Paris 05, Paris, France

来源：

JOURNAL OF CROHNS & COLITIS | 2010年 / 4卷 / 04期

关键词：

Inflammatory bowel diseases; Crohn's disease; Ulcerative colitis; Anti-TNF therapy; Immunogenicity; Pharmacology; ANTITUMOR NECROSIS FACTOR; FISTULIZING CROHNS-DISEASE; INFLIXIMAB DOSE INTENSIFICATION; SCHEDULED MAINTENANCE TREATMENT; NEONATAL FC-RECEPTOR; RHEUMATOID-ARTHRITIS; MONOCLONAL-ANTIBODY; FACTOR-ALPHA; CLINICAL-RESPONSE; RANDOMIZED-TRIAL;

D O I：

10.1016/j.crohns.2010.04.004

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

The first ECCO pathogenesis workshop focused on anti-TNF therapy failures in inflammatory bowel diseases (IBDs). The overall objective was to better understand and explore primary non response and loss of response to anti-TNF agents in IBD. The outcome of this workshop is presented into two parts. This first section addresses definitions, frequency and pharmacological aspects of anti-TNF therapy failure, including pharmacokinetics of anti-TNF monoclonal antibodies and immune and non-immune mediated clearance of anti-TNF mAbs. The second section concerns the biological roles of TNF and TNF antagonists, including mechanisms of action of anti-TNF agents, and discuss hypothesis regarding their failures and phenomenon of paradoxical inflammation, including the potential role of TNF independent inflammatory pathways. (C) 2010 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.

引用

页码：355 / 366

页数：12

共 70 条

[61] Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a Randomized trial [J].

Van Assche, Gert ;

Magdelaine-Beuzelin, Charlotte ;

D'Haens, Geert ;

Baert, Filip ;

Noman, Maja ;

Vermeire, Severine ;

Ternant, David ;

Watier, Herve ;

Paintaud, Gilles ;

Rutgeerts, Paul .

GASTROENTEROLOGY, 2008, 134 (07) :1861-1868

[62] Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed [J].

van de Putte, BA ;

Atkins, C ;

Malaise, M ;

Sany, J ;

Russell, AS ;

van Riel, PLCM ;

Settas, L ;

Biljsma, JW ;

Todesco, S ;

Dougados, M ;

Nash, P ;

Emery, P ;

Walter, N ;

Kaul, M ;

Fischkoff, S ;

Kupper, H .

ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 (05) :508-516

[63]

Vermeire S, 2002, AM J GASTROENTEROL, V97, P2357

[64]

Vermeire S, 2008, GASTROENTEROLOGY, V134, pA67

[65] Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease [J].

Vermeire, Severine ;

Noman, Maja ;

Van Assche, Gert ;

Baert, Filip ;

D'Haens, Geert ;

Rutgeerts, Paul .

GUT, 2007, 56 (09) :1226-1231

[66] Monoclonal Antibody Pharmacokinetics and Pharmacodynamics [J].

Wang, W. ;

Wang, E. Q. ;

Balthasar, J. P. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 84 (05) :548-558

[67] Adalimumab, a fully human anti-tumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate - The ARMADA trial [J].

Weinblatt, ME ;

Keystone, EC ;

Furst, DE ;

Moreland, LW ;

Weisman, MH ;

Birbara, CA ;

Teoh, LA ;

Fischkoff, SA ;

Chartash, EK .

ARTHRITIS AND RHEUMATISM, 2003, 48 (01) :35-45

[68] Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease [J].

West, R. L. ;

Zelinkova, Z. ;

Wolbink, G. J. ;

Kuipers, E. J. ;

Stokkers, P. C. F. ;

van der Woude, C. J. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2008, 28 (09) :1122-1126

[69] Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis [J].

Wolbink, GJ ;

Vis, M ;

Lems, W ;

Voskuyl, AE ;

de Groot, E ;

Nurmohamed, MT ;

Stapel, S ;

Tak, PP ;

Aarden, L ;

Dijkmans, B .

ARTHRITIS AND RHEUMATISM, 2006, 54 (03) :711-715

[70]

ZABANA Y, 2008, J CROHNS COLITIS S, V2

← 1 2 3 4 5 6 7 →